2247608-27-9
2247608-27-9
Chemical Structure
ITF 3756
- CAS No.: 2247608-27-9
- Formula:C13H11N5O2S
- Molecular Weight:301.32
InChIKey: UFUGFWWXDWPEQE-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C(CN2N=NN=C2C3=CC=CS3)C=C1)NO
Biological Activity: ITF 3756 is a selective, orally active HDAC6 inhibitor. ITF 3756 antagonizes TNF-α-induced activation of the NF-κB pathway. ITF 3756 reduces PD-L1 expression on human monocytes and CD8+ T cells, and exhibits antitumor activity. ITF 3756 can be used in colon cancer-related research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ITF 3756 | 98.55% | ITF 3756 is a selective, orally active HDAC6 inhibitor. ITF 3756 antagonizes TNF-α-induced activation of the NF-κB pathway. ITF 3756 reduces PD-L1 expression on human monocytes and CD8+ T cells, and exhibits antitumor activity. ITF 3756 can be used in colon cancer-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Spadotto V, et al. Correction: HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy. Front Immunol. 2025;16:1645773. Published 2025 Aug 5. [Content Brief]
- [2]. Spadotto V, et al. HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy. Front Immunol. 2025;16:1546939. Published 2025 May 13. [Content Brief]
- [3]. Franzò M, et al. Targeting lipogenesis promotes the synergistic effect of the selective HDAC6 inhibitor ITF3756 with bortezomib in colon cancer cells. Front Pharmacol. 2025;16:1706770. Published 2025 Dec 12. [Content Brief]
Keywords
